A phase III trial of farletuzumab failed to meet its endpoints of significantly increasing progression-free survival or overall survival in ovarian cancer patients.

The MORAb-003-004 clinical trial, also known as FAR-131, was a randomized, double-blind, placebo-controlled, global study of the safety and efficacy of weekly farletuzumab in combination with a platinum standard chemotherapy regimen (carboplatin plus a taxane) in platinum-sensitive ovarian cancer patients in first relapse.